首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation
【24h】

How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation

机译:我们如何评估患有造血祖细胞移植患者的患者对患者的红细胞相容性和输血载体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Multiple hematopoietic progenitor cell (HPC) transplantation options for patients with sickle cell disease (SCD) are currently under investigation. Patients with SCD have a high rate of alloimmunization to red blood cell antigens, often complicating transfusion support. Transfusion reactions, including acute and delayed hemolytic reactions, have been observed despite immunosuppressive regimens. Allogeneic donor transplants have been shown to carry a risk of prolonged reticulocytopenia and acute hemolysis with severe anemia in nonmyeloablative regimens. We discuss our experience providing transfusion support to patients with SCD undergoing HPC transplantation, propose an outline for a complete pretransplantation evaluation, and discuss donor/recipient compatibility issues and their implications.
机译:目前正在调查镰状细胞疾病(SCD)患者的多种造血祖细胞(HPC)移植方案。 SCD患者对红细胞抗原具有高速率的同种异体率,通常使输血载体复杂化。 尽管存在免疫抑制方案,已经观察到输血反应,包括急性和延迟的溶血反应。 已显示同种异体供体移植患者患有长时间细胞缺乏症和急性溶血的风险,在非植物方案中具有严重贫血。 我们讨论了对HPC移植进行SCD患者提供输血支持的经验,提出了完整的预体评估的概要,并讨论捐赠者/受援者兼容性问题及其影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号